ライフサイエンスコーパス: respiratory distress

1 have been described in patients with severe respiratory distress.

2 rfactant homeostasis and manifests as lethal respiratory distress.

3 vere anemia, and 441/2239 (19.7%) had severe respiratory distress.

4 sease in adult COVID-19 patients with severe respiratory distress.

5 e anaemia, and 441/2,239 (19.7%) with severe respiratory distress.

6 on by decreasing oxygen exchange, leading to respiratory distress.

7 crosomia, infant birth injury, hypoglycemia, respiratory distress, 5-minute Apgar score less than 7,

8 Newborn infants with respiratory distress and a birth weight of at least 1200

9 phenotype, early onset myopathy, areflexia, respiratory distress and dysphagia, is severe and immedi

10 orne zoonotic pathogen that can cause severe respiratory distress and encephalitis upon spillover int

11 in May 2018 presented as encephalitis, acute respiratory distress and myocarditis or combinations of

12 VID-19, resulting in cases of mild to severe respiratory distress and significant mortality.

13 report describes a cat suffering from severe respiratory distress and thrombocytopenia living with a

14 ate factors: the initial cardiac arrest (and respiratory distress) and the recurrent seizures that fo

15 ere anaemia, elevated lactate concentration, respiratory distress, and parasite density were associat

16 irst time; cold sweat, intraoral discomfort, respiratory distress, and urticaria appeared throughout

17 pergillosis in COVID-19 patients with severe respiratory distress are being reported, but comprehensi

18 patients (including patients with no initial respiratory distress) as survivors and nonsurvivors with

19 d with perinatal outcome, including hydrops, respiratory distress at birth, need for supplemental oxy

20 Acute respiratory distress in macaques and baboons recapitulat

21 orrelated with the incidence and severity of respiratory distress in pneumonia patients.

22 stemic PKCepsilon blockade reduces asthmatic respiratory distress in response to allergen and airway

23 psilon-blocking peptide suppresses asthmatic respiratory distress in response to allergen and reduces

24 cted in the neonatal lung, which may lead to respiratory distress, infection, and pneumothorax.

25 es: large for gestational age, hypoglycemia, respiratory distress, low Apgar score, neonatal death, a

26 erinatal complications including septicemia, respiratory distress, low birth weight, and spontaneous

27 Patients typically present with neonatal respiratory distress of unknown cause and then continue

28 The authors found that respiratory distress on admission is associated with unf

29 (RR, 1.24; 95% CI, 1.05-1.46), and neonatal respiratory distress (RR, 1.20; 95% CI, 1.02-1.42).

30 extrapulmonary compared with pulmonary acute respiratory distress syndrome (10 mm Hg [7-12 mm Hg] vs

31 [71%], P = .01) and development of the acute respiratory distress syndrome (20 of 20 patients [100%]

32 3%), transaminitis (31%), shock (31%), acute respiratory distress syndrome (25%), neurological events

33 eath in the 1109 infants were established as respiratory distress syndrome (502 [45%]); sepsis, pneum

34 us 86.4% of patients without pediatric acute respiratory distress syndrome (adjusted relative risk, 1

35 1.7% among patients without pediatric acute respiratory distress syndrome (adjusted relative risk, 3

36 ve sedated and paralyzed patients with acute respiratory distress syndrome (age 64 +/- 15 yr, body ma

37 , and interleukin-8 than those without acute respiratory distress syndrome (all p < 0.003).

38 1.142, 95% CI 1.059-1.231, p < 0.001), acute respiratory distress syndrome (ARDS) (OR: 10.142, 95% CI

39 it is associated with inflammation and acute respiratory distress syndrome (ARDS) and may have the ap

40 enin-angiotensin-aldosterone system in acute respiratory distress syndrome (ARDS) and respiratory fai

41 19 (COVID-19)- vs non-COVID-19-induced acute respiratory distress syndrome (ARDS) at a single US acad

42 Acute respiratory distress syndrome (ARDS) caused by SARS-CoV-

43 Acute respiratory distress syndrome (ARDS) due to coronavirus

44 tingly, its use in adults for treating acute respiratory distress syndrome (ARDS) experienced initial

45 lly plausible as a strategy to prevent acute respiratory distress syndrome (ARDS) in coronavirus dise

46 ith urgent evaluation of patients with acute respiratory distress syndrome (ARDS) in the emergency ro

47 ratory symptoms, which can progress to acute respiratory distress syndrome (ARDS) in the most severe

48 s coronavirus 2019 (COVID-19) disease, acute respiratory distress syndrome (ARDS) is a common and oft

49 The acute respiratory distress syndrome (ARDS) is a common cause o

50 Acute respiratory distress syndrome (ARDS) is a common feature

51 Acute respiratory distress syndrome (ARDS) is a heterogeneous

52 Acute respiratory distress syndrome (ARDS) is an inflammatory

53 garding the impact of air pollution on acute respiratory distress syndrome (ARDS) is limited, and mos

54 Rationale: Acute respiratory distress syndrome (ARDS) lacks known causal

55 ) receptor 4 (CXCR4) agonists in a rat acute respiratory distress syndrome (ARDS) model utilizing the

56 on ranging from isolated thrombosis to acute respiratory distress syndrome (ARDS) requiring ventilato

57 ng autopsy from patients who died from acute respiratory distress syndrome (ARDS) secondary to influe

58 COVID-19 can cause acute respiratory distress syndrome (ARDS) that is rapidly pro

59 VID-19 or to treat the immune storm or acute respiratory distress syndrome (ARDS) that often causes s

60 t in ~10-15% of patients progresses to acute respiratory distress syndrome (ARDS) triggered by a cyto

61 njury in severe COVID-19 compared with acute respiratory distress syndrome (ARDS) unrelated to COVID-

62 e unit (ICU) admission, mortality, and acute respiratory distress syndrome (ARDS) were 10.9%, 4.3%, a

63 icosteroids in severe COVID-19-related acute respiratory distress syndrome (ARDS) were associated wit

64 diffuse alveolar inflammation seen in acute respiratory distress syndrome (ARDS) which is currently

65 euromuscular blockade in patients with acute respiratory distress syndrome (ARDS) who are receiving m

66 Rationale: Two distinct phenotypes of acute respiratory distress syndrome (ARDS) with differential c

67 ompare the immunopathology of COVID-19 acute respiratory distress syndrome (ARDS) with that of non-CO

68 e respiratory infections can result in acute respiratory distress syndrome (ARDS)(1).

69 herapy is a promising intervention for acute respiratory distress syndrome (ARDS), although trials to

70 eases such as acute lung injury (ALI), acute respiratory distress syndrome (ARDS), chronic obstructiv

71 In patients with acute respiratory distress syndrome (ARDS), the National Heart

72 In the setting of severe acute respiratory distress syndrome (ARDS), the use of prone a

73 or progress toward a life-threatening acute respiratory distress syndrome (ARDS).

74 which serves as the first event in the acute respiratory distress syndrome (ARDS).

75 echanical ventilation in patients with acute respiratory distress syndrome (ARDS).

76 text of coronavirus disease (COVID-19) acute respiratory distress syndrome (ARDS).

77 eatures of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS).

78 e caused by COVID-19 and might prevent acute respiratory distress syndrome (ARDS).

79 utor to the morbidity and mortality of acute respiratory distress syndrome (ARDS).

80 EP) in critically ill patients without acute respiratory distress syndrome (ARDS).

81 rom mild pneumonia to life-threatening acute respiratory distress syndrome (ARDS).

82 es in a critically ill population with acute respiratory distress syndrome (ARDS).

83 injury and repair is a hallmark of the acute respiratory distress syndrome (ARDS).

84 critically ill patients with COVID-19 acute respiratory distress syndrome (ARDS).

85 isk factor for acute lung injury (ALI)/acute respiratory distress syndrome (ARDS).

86 have been recommended in patients with acute respiratory distress syndrome (ARDS).Objectives: To dete

87 cohort, models for intubated pediatric acute respiratory distress syndrome (including and excluding n

88 5.4% of nonsurvivors without pediatric acute respiratory distress syndrome (p = 0.001).

89 PEEPPL in subjects with extrapulmonary acute respiratory distress syndrome (p = 0.006), whereas the o

90 as the opposite was true for pulmonary acute respiratory distress syndrome (p = 0.03).

91 ly adjunctive therapy use in pediatric acute respiratory distress syndrome (PARDS).Objectives: To des

92 Respiratory Distress Syndrome (RDS) is the commonest dia

93 rapeutic treatment in neonatal patients with respiratory distress syndrome (RDS).

94 evere oxygen dependence (stage 2b) and acute respiratory distress syndrome (stage 3) associated with

95 l malaria [CM] = 2.42 [1.24-4.72], p = 0.01; respiratory distress syndrome [RDS] = 4.09 [1.70-9.82],

96 d higher in sepsis with versus without acute respiratory distress syndrome after multivariable analys

97 Lung-protective ventilation for acute respiratory distress syndrome aims for providing suffici

98 one-class models in both patients with acute respiratory distress syndrome and ARFA.

99 d review complement's role in COVID-19 acute respiratory distress syndrome and coagulopathy.

100 y state ("cytokine storm") followed by acute respiratory distress syndrome and death.

101 ulation of angiotensin II that induces acute respiratory distress syndrome and fulminant myocarditis.

102 , there were two deaths (one each from acute respiratory distress syndrome and hemorrhage from esopha

103 ute respiratory syndrome coronavirus 2 acute respiratory distress syndrome and high compliance improv

104 e care among patients with and without acute respiratory distress syndrome and hospital resource util

105 xtracorporeal membrane oxygenation for acute respiratory distress syndrome and in different subgroups

106 or sepsis patients with versus without acute respiratory distress syndrome and in relation to complic

107 Clinician diagnosis of acute respiratory distress syndrome and inclusion of acute res

108 dysfunction is common in patients with adult respiratory distress syndrome and is associated with mor

109 ical interstitial bilateral pneumonia, acute respiratory distress syndrome and multiorgan dysfunction

110 monstrated good discrimination between acute respiratory distress syndrome and nonacute respiratory d

111 timated associations between pediatric acute respiratory distress syndrome and outcome using generali

112 rate of barotrauma than patients with acute respiratory distress syndrome and patients without COVID

113 eptococcus coinfection, progressing to acute respiratory distress syndrome and shock.

114 na virus 2 pneumonia is linked to both acute respiratory distress syndrome and systemic hypercoagulab

115 f glycocalyx degradation in unraveling acute respiratory distress syndrome and the cardiovascular, mi

116 c therapies to avert potentially fatal acute respiratory distress syndrome and treat hyperinflammator

117 injury (ALI) and its more severe form, acute respiratory distress syndrome are life-threatening disea

118 cision making for management of severe acute respiratory distress syndrome at centres providing venov

119 rtality was 50.0% for severe pediatric acute respiratory distress syndrome at onset, 33.3% for modera

120 not only in patients with established acute respiratory distress syndrome but also in patients at ri

121 ing oxygenation criteria for pediatric acute respiratory distress syndrome but without bilateral infi

122 ng which 110 (47%) were diagnosed with acute respiratory distress syndrome by expert annotation.

123 n the model had good face validity for acute respiratory distress syndrome characteristics but differ

124 The underlying etiology of acute respiratory distress syndrome could deeply influence res

125 hether patients met complete pediatric acute respiratory distress syndrome criteria via chart review.

126 red children, 103 (4.2%) met pediatric acute respiratory distress syndrome criteria.

127 gh this practical approach has reduced acute respiratory distress syndrome deaths, mortality is still

128 tive end-expiratory pressure (PEEP) in acute respiratory distress syndrome depends on recruitability.

129 n previously recognized, and pediatric acute respiratory distress syndrome development is associated

130 to predict ICU outcome at 24 hours of acute respiratory distress syndrome diagnosis.

131 The 2015 definition for pediatric acute respiratory distress syndrome did not require the presen

132 l life support in patients with severe acute respiratory distress syndrome during the influenza A(H1N

133 affecting critically ill patients with acute respiratory distress syndrome following severe acute res

134 nd mortality associated with pediatric acute respiratory distress syndrome following traumatic injury

135 or identifying high-risk patients with acute respiratory distress syndrome for enrollment into random

136 pathophysiological characteristics of acute respiratory distress syndrome from coronavirus disease 2

137 In patients with acute respiratory distress syndrome from coronavirus disease 2

138 e to barotrauma rates of patients with acute respiratory distress syndrome from February 1, 2016, to

139 tive observational cohort of pediatric acute respiratory distress syndrome from the Children's Hospit

140 Our computable phenotype for acute respiratory distress syndrome had good discrimination in

141 Among patients with sepsis, those with acute respiratory distress syndrome had higher angiopoietin-2/

142 Patients with acute respiratory distress syndrome had higher prevalence of c

143 ildren with extrapulmonary sepsis with acute respiratory distress syndrome had plasma biomarkers indi

144 l, physical, and social recovery after acute respiratory distress syndrome hospitalization for at lea

145 den(s) that they associated with their acute respiratory distress syndrome hospitalization.

146 atory disease, with cytokine storm and acute respiratory distress syndrome implicated in the most sev

147 ly injure the functional lung units of acute respiratory distress syndrome in a positive feedback cyc

148 2-induced cytokine storm, which drives acute respiratory distress syndrome in coronavirus disease 201

149 ory distress syndrome and inclusion of acute respiratory distress syndrome in the differential diagno

150 ergone a trial of rescue therapies for acute respiratory distress syndrome including lung protective

151 spontaneous breathing in patients with acute respiratory distress syndrome independent of acute respi

152 inical observation suggests that early acute respiratory distress syndrome induced by the severe acut

153 Acute respiratory distress syndrome is a clinical syndrome cha

154 Recognition is crucial because acute respiratory distress syndrome is associated with a high

155 Clinician recognition of acute respiratory distress syndrome is associated with both sy

156 In the early stage, pulmonary acute respiratory distress syndrome is characterized by a grea

157 The acute respiratory distress syndrome is common in critically il

158 Acute respiratory distress syndrome is frequently under recogn

159 Pediatric acute respiratory distress syndrome is heterogeneous, with a p

160 Survival from acute respiratory distress syndrome is improving, and outcomes

161 xic respiratory failure complicated by acute respiratory distress syndrome is the leading cause of de

162 setup for the first time a long-term (72 hr) respiratory distress syndrome model in spontaneously bre

163 cal ventilation when viewed through an acute respiratory distress syndrome model.

164 Acute respiratory distress syndrome mortality did not change o

165 ording to the intervention arms of the acute respiratory distress syndrome network and the positive e

166 Patients were ventilated with the acute respiratory distress syndrome network and, subsequently,

167 The Acute Respiratory Distress Syndrome Network dataset had limite

168 d from the low tidal volume arm of the Acute Respiratory Distress Syndrome Network tidal volume trial

169 le organ failure in 34.3% of pediatric acute respiratory distress syndrome nonsurvivors versus neurol

170 However, acute respiratory distress syndrome often goes unrecognized.

171 Of 285 patients with acute respiratory distress syndrome on invasive mechanical ven

172 ed lung injury in patients with severe acute respiratory distress syndrome on venovenous extracorpore

173 and PaO2/FIO2 6 hours after pediatric acute respiratory distress syndrome onset.

174 to identify patients meeting pediatric acute respiratory distress syndrome oxygenation criteria for g

175 Children meeting pediatric acute respiratory distress syndrome oxygenation criteria with

176 se patients from the perspective of an acute respiratory distress syndrome paradigm to see if any spe

177 pathways was explored ex vivo in human acute respiratory distress syndrome patient samples, in vitro

178 e respiratory distress syndrome and nonacute respiratory distress syndrome patients (C-statistic, 0.7

179 us 30.7% of patients without pediatric acute respiratory distress syndrome patients (p < 0.001), and

180 orical control group of 39 consecutive acute respiratory distress syndrome patients admitted to the I

181 lue higher than previously reported in acute respiratory distress syndrome patients but with large va

182 < 0.001), and only 17.5% of pediatric acute respiratory distress syndrome patients discharged home w

183 ted in a cohort of intubated pediatric acute respiratory distress syndrome patients from the Children

184 Among survivors, 77.1% of pediatric acute respiratory distress syndrome patients had functional di

185 lator-induced lung injury may occur in acute respiratory distress syndrome patients on venovenous ext

186 otential of such technique in treating acute respiratory distress syndrome patients remains to be inv

187 ; 0.96-1.06) nor did the proportion of acute respiratory distress syndrome patients requiring postdis

188 e protective mechanical ventilation in acute respiratory distress syndrome patients supported with ve

189 Mortality was 34.0% among pediatric acute respiratory distress syndrome patients versus 1.7% among

190 Mortality was 20.0% among acute respiratory distress syndrome patients versus 4.3% among

191 The first 44 coronavirus disease 2019 acute respiratory distress syndrome patients were compared wit

192 spital mortality increased from 31% in acute respiratory distress syndrome patients with no acute kid

193 was to evaluate in a large database of acute respiratory distress syndrome patients, the pulmonary ve

194 syndrome patients versus 4.3% among nonacute respiratory distress syndrome patients, with an adjusted

195 y a CT scan in mechanically ventilated acute respiratory distress syndrome patients.

196 -expiratory pressure levels, pulmonary acute respiratory distress syndrome presented a significantly

197 Although acute respiratory distress syndrome recognition and low tidal

198 1% use of tidal volume <= 6.5 mL/kg if acute respiratory distress syndrome recognized vs 15% if not r

199 ease syndrome that eventually leads to acute respiratory distress syndrome requiring invasive mechani

200 s develop severe disease that leads to acute respiratory distress syndrome requiring prolonged stays

201 Increased acute respiratory distress syndrome severity (p = 0.01) and va

202 atory distress syndrome independent of acute respiratory distress syndrome severity, the use of contr

203 ratory pressure setting in adults with acute respiratory distress syndrome studies.

204 the mortality of patients with severe acute respiratory distress syndrome supported with venovenous

205 Forty-six of 79 eligible acute respiratory distress syndrome survivors (58%) participat

206 order symptoms among family members of acute respiratory distress syndrome survivors is high.

207 ay were all significantly longer among acute respiratory distress syndrome survivors.

208 Severe COVID-19 patients develop acute respiratory distress syndrome that may progress to cytok

209 ation of ART (Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial), when 115 of a plan

210 reported composite outcome measure in acute respiratory distress syndrome trials.

211 iratory syndrome coronavirus 2-related acute respiratory distress syndrome using CT scan imaging desp

212 tive models for mortality in pediatric acute respiratory distress syndrome using readily available va

213 Diagnosing acute respiratory distress syndrome was associated with lower

214 venovenous ECMO in adults with severe acute respiratory distress syndrome was associated with reduce

215 he chart for terms that indicated that acute respiratory distress syndrome was diagnosed, in the diff

216 Acute respiratory distress syndrome was recognized in 70% of p

217 entilatory management of patients with acute respiratory distress syndrome was relatively limited, wi

218 sepsis, and muscle relaxants in severe acute respiratory distress syndrome were not replicated in sub

219 lets (n = 6/group) with surfactant-deficient respiratory distress syndrome were randomized to three c

220 sponses to PEEP.Methods: Patients with acute respiratory distress syndrome were ventilated at 15 and

221 wed improved performance in diagnosing acute respiratory distress syndrome when compared to a rule-ba

222 model had a higher discrimination for acute respiratory distress syndrome when compared with the sta

223 able variables from day 0 of pediatric acute respiratory distress syndrome which outperform severity

224 recruitability in patients with severe acute respiratory distress syndrome who require extracorporeal

225 ory pressure (9 cm H2O) after inducing acute respiratory distress syndrome with oleic acid.

226 rapulmonary sepsis with versus without acute respiratory distress syndrome would have plasma biomarke

227 28 per patient with moderate to severe acute respiratory distress syndrome would represent good value

228 g (e.g., duration of delirium, sepsis, acute respiratory distress syndrome), and after (e.g., early s

229 severe pathological conditions such as acute respiratory distress syndrome, acute chest syndrome, and

230 Decades of clinical research in acute respiratory distress syndrome, acute respiratory failure

231 d mortality attributable to pneumonia, acute respiratory distress syndrome, and multiorgan failure.

232 Encephalitis, acute respiratory distress syndrome, and myocarditis were the

233 asthma, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, and pulmonary arterial hy

234 mechanical ventilation, development of acute respiratory distress syndrome, and receipt of vasopresso

235 talized for COVID-19, four of whom had acute respiratory distress syndrome, and six healthy controls.

236 form, the disease is characterized by acute respiratory distress syndrome, and there are no targeted

237 lung injury and its more severe form, acute respiratory distress syndrome, are life-threatening resp

238 g used to support patients with severe acute respiratory distress syndrome, but its cost-effectivenes

239 is the reference imaging technique for acute respiratory distress syndrome, but requires transportati

240 ults in major complications, including acute respiratory distress syndrome, disseminated intravascula

241 astatic infection, multiorgan failure, acute respiratory distress syndrome, disseminated intravascula

242 common indication for tracheostomy was acute respiratory distress syndrome, followed by failure to we

243 d sibling, low level of Hemoglobin at birth, respiratory distress syndrome, low Hemoglobin level, blo

244 elated to sepsis, respiratory failure, acute respiratory distress syndrome, or multiple organ dysfunc

245 In experimental mild-to-moderate acute respiratory distress syndrome, positive end-expiratory p

246 d patients with influenza A(H1N1)pdm09 acute respiratory distress syndrome, prevalence of the H275Y s

247 l toxicity manifested in patients with acute respiratory distress syndrome, protective factors agains

248 f coronavirus disease 2019 develop the acute respiratory distress syndrome, requiring admission to th

249 ipal diagnoses of respiratory failure, acute respiratory distress syndrome, respiratory arrest, or se

250 In sepsis without acute respiratory distress syndrome, soluble fms-like tyrosine

251 ing development of pulmonary embolism, acute respiratory distress syndrome, systemic inflammatory res

252 Because IL-6 is a relevant cytokine in acute respiratory distress syndrome, the blockade of its recep

253 nous) ECMO and characterised as having acute respiratory distress syndrome, the estimated cumulative

254 In newborn piglets with respiratory distress syndrome, the nebulization of 400 m

255 ve pulmonary complications (pneumonia, acute respiratory distress syndrome, unexpected ventilation).

256 pondents reported not working prior to acute respiratory distress syndrome, using Medicaid or Medicar

257 gA titers seen in patients with severe acute respiratory distress syndrome, whereas mild disease may

258 CoV-2 predicted the odds of developing acute respiratory distress syndrome, which increased by 62% (C

259 Thirty-one of 46 reported at least one acute respiratory distress syndrome-related financial impact.

260 ents reported multiple consequences of acute respiratory distress syndrome-related financial toxicity

261 ratory infection to potentially lethal acute respiratory distress syndrome.

262 ion models for patients with pediatric acute respiratory distress syndrome.

263 y pressure in patients affected by the acute respiratory distress syndrome.

264 sis-associated organ injury, including acute respiratory distress syndrome.

265 ses diffuse alveolar damage leading to acute respiratory distress syndrome.

266 s an explanation for sepsis-associated acute respiratory distress syndrome.

267 othelial activation than those without acute respiratory distress syndrome.

268 onary pressure in patients affected by acute respiratory distress syndrome.

269 toxicity to survivors' lives following acute respiratory distress syndrome.

270 ng pulmonary fibrosis, thrombosis, and acute respiratory distress syndrome.

271 nt host immune response can lead to an acute respiratory distress syndrome.

272 ay epithelium and in lungs can lead to acute respiratory distress syndrome.

273 r bronchoalveolar lavages, piglets developed respiratory distress syndrome.

274 ute hypoxemic respiratory failure, and acute respiratory distress syndrome.

275 ripheral vascular disease, sepsis, and acute respiratory distress syndrome.

276 nly in those without sepsis-associated acute respiratory distress syndrome.

277 al ventilation, presence of shock, and acute respiratory distress syndrome.

278 nts had a pulmonary and extrapulmonary acute respiratory distress syndrome.

279 ections of the morphologic patterns in acute respiratory distress syndrome.

280 may guide the ventilatory strategy in acute respiratory distress syndrome.

281 ost-effective for patients with severe acute respiratory distress syndrome.

282 rich edema formation, the hallmarks of acute respiratory distress syndrome.

283 tal mortality during the first week of acute respiratory distress syndrome.

284 ne oxygenation (ECMO) in patients with acute respiratory distress syndrome.

285 ease utilization of proning for severe acute respiratory distress syndrome.

286 atients with influenza A pneumonia and adult respiratory distress syndrome.

287 ead space compared with extrapulmonary acute respiratory distress syndrome.

288 propriate signaling has been linked to acute respiratory distress syndrome.

289 serum IgA were correlated with severe acute respiratory distress syndrome.

290 ext from radiology reports to identify acute respiratory distress syndrome.

291 ates lung injury in an animal model of acute respiratory distress syndrome.

292 e gas exchange in patients with severe acute respiratory distress syndrome.

293 ity is a risk factor for pneumonia and acute respiratory distress syndrome.

294 d healing of the "baby lung" of severe acute respiratory distress syndrome.

295 overy after critical illnesses such as acute respiratory distress syndrome.

296 s also associated with the presence of acute respiratory distress syndrome.Conclusions: Key features

297 f embryonic mice resulted in neonatal lethal respiratory distress that was associated with negative i

298 inhaling Bacillus anthracis spores, leads to respiratory distress, vascular leakage, high-level bacte

299 ants presenting with fever in the absence of respiratory distress who required hospitalization for ev

300 Untreated SP-B deficient mice develop fatal respiratory distress within two days.